Triomics Secures $22M to Advance Oncology-Specific AI in Cancer Centers

Triomics, a pioneering startup dedicated to transforming oncology care through artificial intelligence, has successfully secured $22 million in Series B funding. This significant investment, led by Battery Ventures with participation from existing investors including Nexus Venture Partners, Lightspeed, and Y Combinator, will accelerate the deployment of its AI-powered platform to cancer centers, helping oncologists and administrative staff automate crucial, data-intensive tasks. The landscape of cancer treatment has evolved, leading to remarkable breakthroughs that extend patients' lives. However, this progress has also resulted in incredibly dense, multi-year medical records, often spanning thousands of pages of physician notes, imaging reports, and even scanned faxes. Reviewing and deciphering these complex histories consumes an immense amount of healthcare staff time, contributing to burnout and reducing the precious moments oncologists can spend directly with their patients. Founded in 2021, Triomics initially focused on leveraging AI to match patients with the most suitable clinical trials. As large language model (LLM) capabilities advanced, the company expanded its platform significantly. Over the past two years, Triomics introduced verifiable patient summaries, delivering critical information directly into existing clinical tools, thereby eliminating the need for clinicians to switch applications. This innovation drastically cuts down appointment preparation time and streamlines administrative workflows. What sets Triomics apart from more generic AI agents or general medical scribes, such as Abridge and Microsoft's Nuance, is its specialized approach. The company's AI models are meticulously trained on vast datasets of oncology-specific information, ensuring accuracy and relevance for complex cancer cases. This targeted expertise has garnered the trust of prominent institutions like Memorial Sloan Kettering (MSK) and Yale Cancer Center, which utilize Triomics to automate tasks ranging from generating patient summaries to submitting mandatory tumor reports to government registries. The impact of Triomics' platform is evident in its rapid growth. According to co-founder Sarim Khan, the startup has quadrupled its enterprise customer base over the last year, driving a remarkable tenfold increase in annualized recurring revenue. By alleviating the administrative burden on healthcare professionals, Triomics not only enhances operational efficiency but also empowers oncologists to dedicate more time to patient care, ultimately improving outcomes in the challenging field of oncology.